Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Circassia Pharmaceuticals ( (GB:NIOX) ) has provided an announcement.
NIOX Group plc has confirmed that as of 30 January 2026 its issued share capital consists of 417,934,328 ordinary shares, each carrying one voting right, with no shares held in treasury. The updated total follows the exercise of employee share options over 37,481 ordinary shares, with the new shares admitted via existing block listings and ranking pari passu with existing stock, providing shareholders with an updated denominator for calculating disclosure thresholds under UK transparency rules.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £86.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.
Circassia Pharmaceuticals’ overall stock score is driven by its strong financial performance and positive corporate events, which are offset by neutral technical indicators and a high P/E ratio suggesting overvaluation. The company’s robust cash flow and low leverage provide a stable foundation, while recent corporate actions signal confidence in future growth.
To see Spark’s full report on GB:NIOX stock, click here.
More about Circassia Pharmaceuticals
NIOX Group plc is a UK-listed company on AIM. The announcement relates to its share capital and voting rights structure rather than its specific products, services or market focus, which are not detailed in the release.
Average Trading Volume: 1,114,873
Technical Sentiment Signal: Buy
Current Market Cap: £281.7M
See more insights into NIOX stock on TipRanks’ Stock Analysis page.